Catherine C. Turkel, Chief Development Officer at Novus Therapeutics, Inc. (NVUS), bought 22,222 shares at $9.99 ($222K) on 2017-05-10, disclosed to the SEC on 2017-05-11.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.99 | 11,111 | $111K | 50.0% |
| 2 | $9.99 | 11,111 | $111K | 50.0% |
| Total | $9.99 avg | 22,222 | $222K | 100% |
| Filing → |
| NVUS | SELL | 2019-05-22 | $19K | — | Filing → |
| NVUS | BUY | 2018-09-13 | $322K | — | Filing → |
| NVUS | BUY | 2018-09-07 | $3K | — | Filing → |